{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:17:06Z","timestamp":1792639026811,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T00:00:00Z","timestamp":1503619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T00:00:00Z","timestamp":1503619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic myeloid leukemia (CML) is characterized by abnormal proliferation of myeloid cells which when untreated leads to bone marrow failure. Imatinib mesylate (IM) is the first line of therapy for treatment of CML and results in remission in most cases. However, a significant percentage of patients develop chemoresistance to IM, which might be due to the presence of chemoresistant cells in the bone marrow. In the current study, we explored the role of cell-cell interaction of CML cells with the bone marrow stromal cells in the development of chemoresistance in CML. We found that the stromal cells offered long-term chemoprotection to the CML cells from the apoptotic effect of IM. These stroma interacting CML cells were maintained in a non-proliferative stage and had increased ERK1\/2 and SMAD1\/8 phosphorylation levels. Prolonged interaction of CML cells with the stromal cells in the presence of IM resulted in the acquisition of stroma-free chemoresistance to IM treatment. However, inhibition of actin cytoskeleton, ERK1\/2 and SMAD signaling abrogated the chemoresistance acquisition and sensitized the chemoresistant CML cells to IM induced apoptosis.<\/jats:p>","DOI":"10.1038\/s41598-017-10373-3","type":"journal-article","created":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T15:12:52Z","timestamp":1503328372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Adhesion to stromal cells mediates imatinib resistance in chronic myeloid leukemia through ERK and BMP signaling pathways"],"prefix":"10.1038","volume":"7","author":[{"given":"Atul","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jina","family":"Bhattacharyya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bithiah Grace","family":"Jaganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,25]]},"reference":[{"key":"10373_CR1","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker, B. J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine \n                           355, 2408\u20132417, doi:10.1056\/Nejmoa062867 (2006).","journal-title":"New England Journal of Medicine"},{"key":"10373_CR2","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1111\/j.1349-7006.2012.02346.x","volume":"103","author":"Y Maru","year":"2012","unstructured":"Maru, Y. Molecular biology of chronic myeloid leukemia. Cancer Science \n                           103, 1601\u20131610, doi:10.1111\/j.1349-7006.2012.02346.x (2012).","journal-title":"Cancer Science"},{"key":"10373_CR3","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1128\/MCB.21.3.840-853.2001","volume":"21","author":"XW Zhang","year":"2001","unstructured":"Zhang, X. W., Subrahmanyam, R., Wong, R., Gross, A. W. & Ren, R. B. The NH2-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl. Molecular and Cellular Biology \n                           21, 840\u2013853, doi:10.1128\/Mcb.21.3.840-853.2001 (2001).","journal-title":"Molecular and Cellular Biology"},{"key":"10373_CR4","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/j.1460-2075.1994.tb06319.x","volume":"13","author":"L Puil","year":"1994","unstructured":"Puil, L. et al. Bcr-Abl Oncoproteins Bind Directly to Activators of the Ras Signaling Pathway. Embo Journal \n                           13, 764\u2013773 (1994).","journal-title":"Embo Journal"},{"key":"10373_CR5","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S1535-6108(02)00074-0","volume":"1","author":"M Sattler","year":"2002","unstructured":"Sattler, M. et al. Critical role for Gab2 in transformation by BCR\/ABL. Cancer Cell \n                           1, 479\u2013492, doi:10.1016\/S1535-6108(02)00074-0 (2002).","journal-title":"Cancer Cell"},{"key":"10373_CR6","doi-asserted-by":"publisher","first-page":"11746","DOI":"10.1073\/pnas.92.25.11746","volume":"92","author":"AB Raitano","year":"1995","unstructured":"Raitano, A. B., Halpern, J. R., Hambuch, T. M. & Sawyers, C. L. The Bcr-Abl Leukemia Oncogene Activates Jun Kinase and Requires Jun for Transformation. Proceedings of the National Academy of Sciences of the United States of America \n                           92, 11746\u201311750, doi:10.1073\/pnas.92.25.11746 (1995).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10373_CR7","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood.V86.2.726.bloodjournal862726","volume":"86","author":"T Skorski","year":"1995","unstructured":"Skorski, T. et al. Phosphatidylinositol-3 Kinase-Activity Is Regulated by Bcr\/Abl and Is Required for the Growth of Philadelphia-Chromosome-Positive Cells. Blood \n                           86, 726\u2013736 (1995).","journal-title":"Blood"},{"key":"10373_CR8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nchembio.775","volume":"8","author":"O Hantschel","year":"2012","unstructured":"Hantschel, O. et al. BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nature Chemical Biology \n                           8, 285\u2013293, doi:10.1038\/Nchembio.775 (2012).","journal-title":"Nature Chemical Biology"},{"key":"10373_CR9","doi-asserted-by":"publisher","first-page":"31704","DOI":"10.1074\/jbc.271.49.31704","volume":"271","author":"RL Ilaria","year":"1996","unstructured":"Ilaria, R. L. & VanEtten, R. A. P210 and P190(BCR\/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. Journal of Biological Chemistry \n                           271, 31704\u201331710 (1996).","journal-title":"Journal of Biological Chemistry"},{"key":"10373_CR10","doi-asserted-by":"publisher","unstructured":"Civini, S. et al. Leukemia cells induce changes in human bone marrow stromal cells. Journal of Translational Medicine \n                           11, doi:10.1186\/1479-5876-11-298 (2013).","DOI":"10.1186\/1479-5876-11-298"},{"key":"10373_CR11","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1158\/1535-7163.MCT-07-2331","volume":"7","author":"E Weisberg","year":"2008","unstructured":"Weisberg, E. et al. Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. Molecular Cancer Therapeutics \n                           7, 1121\u20131129, doi:10.1158\/1535-7163.MCT-07-2331 (2008).","journal-title":"Molecular Cancer Therapeutics"},{"key":"10373_CR12","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1158\/1535-7163.MCT-08-0314","volume":"7","author":"NN Bewry","year":"2008","unstructured":"Bewry, N. N. et al. Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Molecular Cancer Therapeutics \n                           7, 3169\u20133175, doi:10.1158\/1535-7163.MCT-08-0314 (2008).","journal-title":"Molecular Cancer Therapeutics"},{"key":"10373_CR13","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1182\/blood-2013-07-518381","volume":"123","author":"E Traer","year":"2014","unstructured":"Traer, E. et al. Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations. Blood \n                           123, 1516\u20131524, doi:10.1182\/blood-2013-07-518381 (2014).","journal-title":"Blood"},{"key":"10373_CR14","doi-asserted-by":"crossref","unstructured":"Schmidt, T. et al. Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia. Cancer Cell \n                           19, 740\u2013753, doi:S1535-6108(11)00165-6 (2011).","DOI":"10.1016\/j.ccr.2011.05.007"},{"key":"10373_CR15","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1182\/blood-2012-02-412890","volume":"121","author":"B Zhang","year":"2013","unstructured":"Zhang, B. et al. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-beta-catenin signaling. Blood \n                           121, 1824\u20131838, doi:10.1182\/blood-2012-02-412890 (2013).","journal-title":"Blood"},{"key":"10373_CR16","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/sj.leu.2404489","volume":"21","author":"R Ramasamy","year":"2007","unstructured":"Ramasamy, R. et al. Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia \n                           21, 304\u2013310, doi:10.1038\/sj.leu.2404489 (2007).","journal-title":"Leukemia"},{"key":"10373_CR17","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/aps.2012.9","volume":"33","author":"YJ Zhang","year":"2012","unstructured":"Zhang, Y. J. et al. Imatinib induces H2AX phosphorylation and apoptosis in chronic myelogenous leukemia cells in vitro via caspase-3\/Msti pathway. Acta Pharmacologica Sinica \n                           33, 551\u2013557, doi:10.1038\/aps.2012.9 (2012).","journal-title":"Acta Pharmacologica Sinica"},{"key":"10373_CR18","doi-asserted-by":"publisher","unstructured":"Jaganathan, B. G., Anjos-Afonso, F., Kumar, A. & Bonnet, D. Active RHOA favors retention of human hematopoietic stem\/progenitor cells in their niche. Journal of Biomedical Science \n                           20, doi:10.1186\/1423-0127-20-66 (2013).","DOI":"10.1186\/1423-0127-20-66"},{"key":"10373_CR19","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.1182\/blood-2013-05-501460","volume":"122","author":"B Laperrousaz","year":"2013","unstructured":"Laperrousaz, B. et al. Primitive CML cell expansion relies on abnormal levels of BMPs provided by the niche and on BMPRIb overexpression. Blood \n                           122, 3767\u20133777, doi:10.1182\/blood-2013-05-501460 (2013).","journal-title":"Blood"},{"key":"10373_CR20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nri2726","volume":"10","author":"A Trumpp","year":"2010","unstructured":"Trumpp, A., Essers, M. & Wilson, A. Awakening dormant haematopoietic stem cells. Nature Reviews Immunology \n                           10, 201\u2013209, doi:10.1038\/nri2726 (2010).","journal-title":"Nature Reviews Immunology"},{"key":"10373_CR21","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1182\/blood-2007-05-087759","volume":"110","author":"YY Jang","year":"2007","unstructured":"Jang, Y. Y. & Sharkis, S. J. A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche. Blood \n                           110, 3056\u20133063, doi:10.1182\/blood-2007-05-087759 (2007).","journal-title":"Blood"},{"key":"10373_CR22","doi-asserted-by":"crossref","unstructured":"Lagadinou, E. D. et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell \n                           12, 329\u2013341, doi:S1934-5909(12)00755-2 (2013).","DOI":"10.1016\/j.stem.2012.12.013"},{"key":"10373_CR23","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.molcel.2008.05.014","volume":"30","author":"MJM Bertrand","year":"2008","unstructured":"Bertrand, M. J. M. et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Molecular Cell \n                           30, 689\u2013700, doi:10.1016\/j.molcel.2008.05.014 (2008).","journal-title":"Molecular Cell"},{"key":"10373_CR24","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.3324\/haematol.2009.017178","volume":"95","author":"F Vianello","year":"2010","unstructured":"Vianello, F. et al. Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4\/CXCL12 axis. Haematologica-the Hematology Journal \n                           95, 1081\u20131089, doi:10.3324\/haematol.2009.017178 (2010).","journal-title":"Haematologica-the Hematology Journal"},{"key":"10373_CR25","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.exphem.2012.05.001","volume":"40","author":"A Zepeda-Moreno","year":"2012","unstructured":"Zepeda-Moreno, A. et al. Modeling SDF-1-induced mobilization in leukemia cell lines. Experimental Hematology \n                           40, 666\u2013674, doi:10.1016\/j.exphem.2012.05.001 (2012).","journal-title":"Experimental Hematology"},{"key":"10373_CR26","doi-asserted-by":"publisher","unstructured":"Sonowal, H., Kumar, A., Bhattacharyya, J., Gogoi, P. K. & Jaganathan, B. G. Inhibition of actin polymerization decreases osteogeneic differentiation of mesenchymal stem cells through p38 MAPK pathway. Journal of Biomedical Science \n                           20, doi:10.1186\/1423-0127-20-71 (2013).","DOI":"10.1186\/1423-0127-20-71"},{"key":"10373_CR27","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s10637-014-0203-5","volume":"33","author":"M Trendowski","year":"2015","unstructured":"Trendowski, M., Mitchell, J. M., Corsette, C. M., Acquafondata, C. & Fondy, T. P. Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models. Investigational New Drugs \n                           33, 290\u2013299, doi:10.1007\/s10637-014-0203-5 (2015).","journal-title":"Investigational New Drugs"},{"key":"10373_CR28","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/cm.20472","volume":"67","author":"M Amano","year":"2010","unstructured":"Amano, M., Nakayama, M. & Kaibuchi, K. Rho-Kinase\/ROCK: A Key Regulator of the Cytoskeleton and Cell Polarity. Cytoskeleton \n                           67, 545\u2013554, doi:10.1002\/cm.20472 (2010).","journal-title":"Cytoskeleton"},{"key":"10373_CR29","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1242\/jcs.064964","volume":"124","author":"ST Sit","year":"2011","unstructured":"Sit, S. T. & Manser, E. Rho GTPases and their role in organizing the actin cytoskeleton. Journal of Cell Science \n                           124, 679\u2013683, doi:10.1242\/jcs.064964 (2011).","journal-title":"Journal of Cell Science"},{"key":"10373_CR30","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/leu.2011.66","volume":"25","author":"LS Steelman","year":"2011","unstructured":"Steelman, L. S. et al. Roles of the Ras\/Raf\/MEK\/ERK pathway in leukemia therapy. Leukemia \n                           25, 1080\u20131094, doi:10.1038\/leu.2011.66 (2011).","journal-title":"Leukemia"},{"key":"10373_CR31","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1182\/blood-2003-04-1271","volume":"103","author":"S Chu","year":"2004","unstructured":"Chu, S., Holtz, M., Gupta, M. & Bhatia, R. BCR\/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34(+) cells. Blood \n                           103, 3167\u20133174, doi:10.1182\/blood-2003-04-1271 (2004).","journal-title":"Blood"},{"key":"10373_CR32","doi-asserted-by":"publisher","first-page":"3712","DOI":"10.1182\/blood-2004-04-1670","volume":"104","author":"M Chatterjee","year":"2004","unstructured":"Chatterjee, M. et al. Combined disruption of both the MEK\/ERK and the IL-6R\/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood \n                           104, 3712\u20133721, doi:10.1182\/blood-2004-04-1670 (2004).","journal-title":"Blood"},{"key":"10373_CR33","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/jmcb\/mjs010","volume":"4","author":"A Puissant","year":"2012","unstructured":"Puissant, A. et al. Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness. Journal of Molecular Cell Biology \n                           4, 207\u2013220, doi:10.1093\/jmcb\/mjs010 (2012).","journal-title":"Journal of Molecular Cell Biology"},{"key":"10373_CR34","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/cyto.a.22118","volume":"81A","author":"C Bourgne","year":"2012","unstructured":"Bourgne, C. et al. Measurement of imatinib uptake by flow cytometry. Cytometry Part A \n                           81A, 996\u20131004, doi:10.1002\/cyto.a.22118 (2012).","journal-title":"Cytometry Part A"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-10373-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-10373-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-10373-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T09:35:12Z","timestamp":1671788112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-10373-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,25]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["10373"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-10373-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,25]]},"assertion":[{"value":"16 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"9535"}}